Biocon Results

Biocon share price pops 2% on CDSCO nod for diabetes drug; key details here

Biocon's share price saw an uptick following key regulatory approvals in India for its Liraglutide drug, which is used in the treatment of type 2 diabetes.

Biocon share rises as arm secures UK MHRA nod for plaque psoriasis drug

Biocon share rose after arm, Biocon Biologics, was granted market authorisation in the UK for Yesintek, a biosimilar of Ustekinumab, from the Medicines and Healthcare products Regulatory Agency (MHRA)

Biocon Q4FY25 results: Consolidated net profit rises 153% to ₹344 crore

Biotech firm Biocon on Thursday said its consolidated net profit surged over two-fold to Rs 344 crore in the fourth quarter ended March 31, 2025 aided by robust sales across business verticals. The company had reported a net profit of Rs 136 crore in the January-March period of the preceding fiscal. Total revenue rose to Rs 4,454 crore in the latest fourth quarter as compared to Rs 3,966 crore in the year-ago period, Biocon Ltd said in a statement. For the year ended March 31, 2025, the company said its net profit declined to Rs 1,013 crore as compared to Rs 1,022 crore in FY24, it added. Total revenue rose to Rs 16,470 crore in FY25 as compared to Rs 15,621 crore recorded in FY24, the company said. "The Biocon Group ended the year with a strong performance across its businesses," Biocon Group Chairperson Kiran Mazumdar-Shaw said. FY25 has been a year of consolidation and transition, she stated. "We are now on a path of accelerating growth with a commitment to innovation, digita

Biocon subsidiary gets USFDA nod for Everolimus tablets; share zooms 6%

The rise in the Biocon share price came after its wholly-owned unit, Biocon Pharma, received USFDA nod for Everolimus tablets.

Biocon Q2 FY25 results: Net profit declines 84% to Rs 27.1 crore

Revenue driven by gains from US Oncology and Insulins franchises

Biocon Q4 results: Profit drops 57% to Rs 135 crore; revenue up 4%

Biocon Q4FY24 results: The company board has recommended a final dividend at the rate of 10 per cent i.e. Re. 0.50 per equity share

Syngene International Q3 results: Profit after tax up 4%; revenue rises 9%

About a week ago, Syngene International's share price declined by 3 per cent following UBS Global Research stock downgrade to sell

Biosimilars growth props up Biocon Q2 PAT by 168% to Rs 126 crore

On a sequential basis, the company exhibited a 1.15 per cent increase in revenue along with PAT, which rose 23.8 per cent

Biocon Q2 results: Net profit zooms over two-fold to Rs 173 crore

Biotechnology major Biocon on Friday said its consolidated net profit rose an over two-fold to Rs 173 crore for the second quarter ended September 30, 2023. The company had reported a net profit of Rs 82 crore for the July-September period of the last fiscal. Total income rose to Rs 3,620 crore for the second quarter as against Rs 2,384 crore in the year-ago period, Biocon Ltd said in a regulatory filing. Shares of the company on Friday ended 0.11 per cent higher at Rs 227.35 apiece on the BSE.

Biocon Biologics gets positive opinion from EMA for ophthalmology product

Yesafili aims to treat various visual impairments and age-related macular degeneration

Biocon Q4 results: Net profit rises 31% to Rs 313 cr, revenue up 57%

For the entire financial year, the company's net profit saw a decline of 29 per cent to Rs 462.7 crore, as compared to Rs 648.4 crore in 2021-22

Biocon Q2 results: Net profit declines 10% to Rs 168 crore, revenue up 26%

Biocon's core Ebitda came in at Rs 816 crore, up 34 per cent

Biocon posts 22% fall in Q2 net profit on high R&D expenses, staff costs

The Bengaluru-headquartered company posted 10 per cent growth in consolidated revenue on a y-o-y basis to Rs 1,760 crore in Q2

Q4 a minor blip in Biocon's growth story, recovery expected in Q1FY21

Analysts estimate 38 per cent annual growth in earnings during FY20-22

Biocon stock gains 15% after US FDA nod for cancer drug, m-cap up Rs 4k cr

The stock however pared some gains and settled at Rs 513.55, up 15 per cent on BSE